ViRexx Presents Hepatitis C Chimigen'TM' Technology at Baculovirus ...

ViRexx Presents Hepatitis C Chimigen'TM' Technology at Baculovirus ...
Genetic Engineering News, NY - Feb 22, 2006... The presentation is titled "Properties of a Chimigen(TM) Vaccine Produced in Insect Cells for the Treatment of Chronic Hepatitis C Infections". ...

Toll-like receptor therapies compete to reduce side effects
Nature.com (subscription), UK - Mar 6, 2006... CSO, claims that ANA975, the company's TLR7 agonist, recently tested in a 28-day clinical trial involving patients with chronic hepatitis C, could produce ...

Peregrine advances hepatitis C drug
Pharmaceutical Business Review - Feb 17, 2006... planned patient enrollment and dosing in its initial phase I clinical trial for Tarvacin anti-viral in the treatment of chronic hepatitis C virus infection. ...

MIGENIX Third Quarter Fiscal 2006 Financial Results Conference ...
Canada NewsWire (press release), Canada - Mar 2, 2006... The Company's clinical programs include drug candidates for the treatment of chronic Hepatitis C infections (Phase II), the prevention of catheter-related ...

Peregrine Antiviral Demonstrates Safety in Hepatitis Patients
International News Service, Australia - Feb 28, 2006... data demonstrating that its first-in-class antiviral compound Tarvacin appeared safe and well-tolerated in a phase I study in patients with chronic hepatitis C ...

AVI BioPharma Successful Ebola Study Results Highlighted in Nature ...
Genetic Engineering News, NY - Mar 7, 2006... infections.". AVI is currently enrolling patients with chronic hepatitis C infection in a Phase I/II clinical trial in the United States. ...